AFFILIATIONS
1 Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
5 Prince of Songkla University, Hat Yai, Songkhla, Thailand
6 Mayo Clinic College of Medicine and Science, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
10 Division of hematology-oncology, Children's Hospital of Philadelphia of The University of Pennsylvania, Philadelphia, Pennsylvania, United States, Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic College of Medicine and Science, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Recent advances in cell therapy led to the FDA approval of B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T (CART) cell therapies for multiple myeloma (MM). While BCMA-CART cells result in short-term remission, most MM patients relapse within 3-5 years. We and others have shown that the MM tumor microenvironment (TME) is highly immunosuppressive with an abundance of macrophages and cancer-associated fibroblasts (CAFs) that inhibit BCMA-CART cell function.
To surmount TME-mediated CART cell dysfunction, we developed novel tri-specific molecules that target CAFs and remodel the MM TME (STriKEs). Our two STriKEs include: 1) an IL-15/anti-FAP/anti-CD16 molecule (1615-FAP STriKE) and 2) an anti-FAP-Fc/anti-SIRPα molecule (SIRPα STriKE). While both STriKEs are designed to abolish immunosuppressive signaling, they are structurally dissimilar and target distinct surface molecules and pathways. Here, we report the biological and mechanistic differences between 1615-FAP STriKE- and SIRPα STriKE rewiring of the MM TME on single-cell and multicellular levels.
We first characterized baseline CAF-macrophage signaling and CART inhibition in vitro. BCMA+ MM cell lines (MM1S or OPM2) were co-cultured with BCMA-CART cells in the presence or absence of donor-matched macrophages and MM patient-derived CAFs. BCMA-CART proliferation and cytotoxicity were significantly reduced in CAF-macrophage co-cultures compared to non-CAF controls (p<0.01). Moreover, supernatants from CART-CAF-macrophage co-cultures contained significantly elevated inhibitory cytokines (TGF-β, IL-4 p<0.01; IL-1β, IL-10 p<0.001). Our findings indicate that CAFs potently modulate CART cell immunosuppression.
To assess STriKE-induced alteration of CAF-macrophage signaling, we performed single-cell RNA sequencing (scRNAseq) of MM patient CAFs co-cultured with macrophages and treated with concentrated, purified supernatants (CPS) from BCMA-CART-STriKEs or controls [untransduced (UTD) T cells or BCMA-CART cells lacking STriKEs]. Macrophages co-cultured with both CPS STriKEs had significantly decreased inhibitory marker expression compared to control CPS (ARG1 p<0.005; CD163 p<0.01). 1615-FAP STriKE CPS treatment significantly downregulated CAF expression of TGF-β (p<0.005) and increased macrophage activation marker expression (IL-12, CD80 p<0.001) compared to BCMA-CART CPS. SIRPα STriKE CPS treatment upregulated antitumor signaling (TNF-α p<0.01; MHC-II, p<0.001) and downregulated inhibitory markers (CD115, CD204, p<0.01). Co-cultures of CFSE+ MM CAFs and macrophages treated with STriKE CPS exhibited significantly increased macrophage-mediated phagocytosis of CAFs compared to BCMA-CART CPS treatment (1615-FAP or SIRPα STriKE CPS vs BCMA-CART CPS, p<0.005). These results suggest that STriKEs modify CAF-macrophage crosstalk via overlapping and distinct mechanisms.
Finally, we studied STriKE function in vivo. Immunocompetent C57BL/6 mice subcutaneously engrafted with human BCMA+ B16 murine cancer cells (1X106 cells) were treated with mouse CART cells targeting human BCMA and secreting murine versions of our STriKEs (5x106 cells). BCMA-CART-STriKE treated mice cleared cancer cells and exhibited long-term tumor control in rechallenge experiments. We next conducted scRNAseq of tumors harvested from satellite mice to examine multicellular and single-cell CAF-CART dynamics. Tumors from STriKE treated mice exhibited significantly higher levels of BCMA-CART infiltration (p<0.001) and reduced B16 cells and murine CAFs compared to UTD or BCMA-CART controls (p<0.001). SIRPα STriKEs led to greater macrophage infiltration, whereas 1615-FAP STriKEs exhibited greater NK cell and pan-monocyte infiltration. CellChat analyses revealed reduced B16 cell-CAF interactions in BCMA-CART-STriKE treated mice compared to control mice. Macrophage-cancer cell interactions were significantly lower in SIRPα STriKE treated mice, while 1615-FAP STriKE treatment resulted in increased T cell-B16, T cell-NK cell, and T cell-macrophage interactions. These findings show that STriKEs successfully remodel the TME in vivo; however, they do so by promoting recruitment of and signaling between distinct sets of cells.
In summary, we have uncovered key differences by which 1615-FAP STriKEs and SIRPα STriKEs remodel the MM TME and enhance BCMA-CART cell efficacy. These results support the development of secreted, multi-cell-targeting molecules to treat a broad array of cancers with immunosuppressive TMEs.